FK506 with rapamycin could effectively improve renal transplantation prognosis, suggests study

A new study published in the journal of BMC Nephrology suggests that FK506 and rapamycin may be able to enhance the outcome of kidney transplantation by lowering interstitial fibrosis, vascular inflammation, and ultimately transplanted kidney rejections.

Over time, chronic kidney disease (CKD) has grown to be a serious worldwide health issue. About 130 million individuals in China suffer from CKD, of which the prevalence is 10.8%. Of them, 1-2% eventually develop end-stage renal disease (ESRD). Replacement treatment, such as peritoneal dialysis, hemodialysis, and allograft kidney transplantation (KTx), is currently the mainstay of care for ESRD patients. Patients are nonetheless suffering from late allograft failure despite significant advancements over the previous few decades. Many variables that impact the prognosis of kidney transplant patients have been widely documented globally in recent years. These variables include recipient baseline data, surgical outcomes, immunosuppressive regimes, and more. Therefore, Yisheng Ji and colleagues undertook this study to assess the impact of rapamycin and the long-term renal transplant prognosis from a single-center in China throughout a 30-year follow-up.

A total of 654 individuals who received kidney transplants between 1989 and 2020 were included in this research. The fundamental attributes of the patients that were involved were gathered. K-M curves, or Kaplan-Meier curves, were employed to compare and characterize graft survival. A multivariate Cox proportional-hazards model had both continuous and categorical variables. The patients were split into two groups, namely the traditional tacrolimus-based triple immunosuppression regimen group (n = 218), and the rapamycin-based quadruple immunosuppression regimen group (n = 41). The frequency of rejection, acute rejection, and banff score were compared between the indication biopsy findings of the two groups.